Heather Feigelson to Cohort Studies
This is a "connection" page, showing publications Heather Feigelson has written about Cohort Studies.
Connection Strength
1.026
-
The Kaiser Permanente Research Bank Cancer Cohort: a collaborative resource to improve cancer care and survivorship. BMC Cancer. 2022 Feb 25; 22(1):209.
Score: 0.127
-
Health care improvement and survivorship priorities of colorectal cancer survivors: findings from the PORTAL colorectal cancer cohort survey. Support Care Cancer. 2019 Jan; 27(1):147-156.
Score: 0.098
-
Weight loss and postmenopausal breast cancer in a prospective cohort of overweight and obese US women. Cancer Causes Control. 2011 Apr; 22(4):573-9.
Score: 0.059
-
Comprehensive analysis of common genetic variation in 61 genes related to steroid hormone and insulin-like growth factor-I metabolism and breast cancer risk in the NCI breast and prostate cancer cohort consortium. Hum Mol Genet. 2010 Oct 01; 19(19):3873-84.
Score: 0.057
-
Genetic variation in candidate obesity genes ADRB2, ADRB3, GHRL, HSD11B1, IRS1, IRS2, and SHC1 and risk for breast cancer in the Cancer Prevention Study II. Breast Cancer Res. 2008; 10(4):R57.
Score: 0.049
-
Adult weight gain and histopathologic characteristics of breast cancer among postmenopausal women. Cancer. 2006 Jul 01; 107(1):12-21.
Score: 0.043
-
Haplotype analysis of the HSD17B1 gene and risk of breast cancer: a comprehensive approach to multicenter analyses of prospective cohort studies. Cancer Res. 2006 Feb 15; 66(4):2468-75.
Score: 0.042
-
Weight gain, body mass index, hormone replacement therapy, and postmenopausal breast cancer in a large prospective study. Cancer Epidemiol Biomarkers Prev. 2004 Feb; 13(2):220-4.
Score: 0.036
-
Alcohol, folate, methionine, and risk of incident breast cancer in the American Cancer Society Cancer Prevention Study II Nutrition Cohort. Cancer Epidemiol Biomarkers Prev. 2003 Feb; 12(2):161-4.
Score: 0.034
-
Treatment-related thoracic soft tissue sarcomas in US breast cancer survivors: a retrospective cohort study. Lancet Oncol. 2022 11; 23(11):1451-1464.
Score: 0.033
-
Molecular markers of risk of subsequent invasive breast cancer in women with ductal carcinoma in situ: protocol for a population-based cohort study. BMJ Open. 2021 10 26; 11(10):e053397.
Score: 0.031
-
Building a multigenic model of breast cancer susceptibility: CYP17 and HSD17B1 are two important candidates. Cancer Res. 2001 Jan 15; 61(2):785-9.
Score: 0.029
-
Association Between Weight Loss and the Risk of Cancer after Bariatric Surgery. Obesity (Silver Spring). 2017 11; 25 Suppl 2:S52-S57.
Score: 0.024
-
Association of Adjuvant Tamoxifen and Aromatase Inhibitor Therapy With Contralateral Breast Cancer Risk Among US Women With Breast Cancer in a General Community Setting. JAMA Oncol. 2017 02 09; 3(2):186-193.
Score: 0.022
-
Interactions between breast cancer susceptibility loci and menopausal hormone therapy in relationship to breast cancer in the Breast and Prostate Cancer Cohort Consortium. Breast Cancer Res Treat. 2016 Feb; 155(3):531-40.
Score: 0.021
-
Screening for peripheral arterial disease: the sensitivity, specificity, and predictive value of noninvasive tests in a defined population. Am J Epidemiol. 1994 Sep 15; 140(6):526-34.
Score: 0.019
-
KRAS testing and epidermal growth factor receptor inhibitor treatment for colorectal cancer in community settings. Cancer Epidemiol Biomarkers Prev. 2013 Jan; 22(1):91-101.
Score: 0.017
-
Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: a retrospective cohort study. J Natl Cancer Inst. 2012 Sep 05; 104(17):1293-305.
Score: 0.016
-
Genome-wide association study identifies new prostate cancer susceptibility loci. Hum Mol Genet. 2011 Oct 01; 20(19):3867-75.
Score: 0.015
-
Comprehensive analysis of hormone and genetic variation in 36 genes related to steroid hormone metabolism in pre- and postmenopausal women from the breast and prostate cancer cohort consortium (BPC3). J Clin Endocrinol Metab. 2011 Feb; 96(2):E360-7.
Score: 0.015
-
A large study of androgen receptor germline variants and their relation to sex hormone levels and prostate cancer risk. Results from the National Cancer Institute Breast and Prostate Cancer Cohort Consortium. J Clin Endocrinol Metab. 2010 Sep; 95(9):E121-7.
Score: 0.014
-
A comprehensive analysis of common IGF1, IGFBP1 and IGFBP3 genetic variation with prospective IGF-I and IGFBP-3 blood levels and prostate cancer risk among Caucasians. Hum Mol Genet. 2010 Aug 01; 19(15):3089-101.
Score: 0.014
-
Performance of common genetic variants in breast-cancer risk models. N Engl J Med. 2010 Mar 18; 362(11):986-93.
Score: 0.014
-
PTGS2 and IL6 genetic variation and risk of breast and prostate cancer: results from the Breast and Prostate Cancer Cohort Consortium (BPC3). Carcinogenesis. 2010 Mar; 31(3):455-61.
Score: 0.014
-
CYP19A1 genetic variation in relation to prostate cancer risk and circulating sex hormone concentrations in men from the Breast and Prostate Cancer Cohort Consortium. Cancer Epidemiol Biomarkers Prev. 2009 Oct; 18(10):2734-44.
Score: 0.013
-
Genetic polymorphisms of the GNRH1 and GNRHR genes and risk of breast cancer in the National Cancer Institute Breast and Prostate Cancer Cohort Consortium (BPC3). BMC Cancer. 2009 Jul 29; 9:257.
Score: 0.013
-
Quantitative trait loci predicting circulating sex steroid hormones in men from the NCI-Breast and Prostate Cancer Cohort Consortium (BPC3). Hum Mol Genet. 2009 Oct 01; 18(19):3749-57.
Score: 0.013
-
Family history of various cancers and pancreatic cancer mortality in a large cohort. Cancer Causes Control. 2009 Oct; 20(8):1261-9.
Score: 0.013
-
Postmenopausal hormone use and breast cancer associations differ by hormone regimen and histologic subtype. Cancer. 2009 Mar 01; 115(5):936-45.
Score: 0.013
-
The role of body weight in the relationship between physical activity and endometrial cancer: results from a large cohort of US women. Int J Cancer. 2008 Oct 15; 123(8):1877-82.
Score: 0.013
-
IGF-1, IGFBP-1, and IGFBP-3 polymorphisms predict circulating IGF levels but not breast cancer risk: findings from the Breast and Prostate Cancer Cohort Consortium (BPC3). PLoS One. 2008 Jul 02; 3(7):e2578.
Score: 0.012
-
Body mass and endometrial cancer risk by hormone replacement therapy and cancer subtype. Cancer Epidemiol Biomarkers Prev. 2008 Jan; 17(1):73-9.
Score: 0.012
-
Sequence variants of estrogen receptor beta and risk of prostate cancer in the National Cancer Institute Breast and Prostate Cancer Cohort Consortium. Cancer Epidemiol Biomarkers Prev. 2007 Oct; 16(10):1973-81.
Score: 0.012
-
Genetic variation at the CYP19A1 locus predicts circulating estrogen levels but not breast cancer risk in postmenopausal women. Cancer Res. 2007 Mar 01; 67(5):1893-7.
Score: 0.011
-
Polymorphisms in the vascular endothelial growth factor gene and breast cancer in the Cancer Prevention Study II cohort. Breast Cancer Res. 2006; 8(2):R22.
Score: 0.011
-
A candidate gene approach to searching for low-penetrance breast and prostate cancer genes. Nat Rev Cancer. 2005 12; 5(12):977-85.
Score: 0.010
-
Breast cancer in a multiethnic cohort in Hawaii and Los Angeles: risk factor-adjusted incidence in Japanese equals and in Hawaiians exceeds that in whites. Cancer Epidemiol Biomarkers Prev. 2002 Sep; 11(9):795-800.
Score: 0.008
-
The American Cancer Society Cancer Prevention Study II Nutrition Cohort: rationale, study design, and baseline characteristics. Cancer. 2002 May 01; 94(9):2490-501.
Score: 0.008
-
Jewish ethnicity and prostate cancer mortality in two large US cohorts. Cancer Causes Control. 2002 Apr; 13(3):271-7.
Score: 0.008
-
The American Cancer Society Cancer Prevention Study II Nutrition Cohort: rationale, study design, and baseline characteristics. Cancer. 2002 Jan 15; 94(2):500-11.
Score: 0.008
-
T1 breast carcinoma in women 70 years of age and older may not require axillary lymph node dissection. Am J Surg. 1996 Nov; 172(5):487-9; discussion 489-90.
Score: 0.005